CEO, Oasis Diagnostics® Corporation and Managing Member of Bamburgh Marrsh LLC, Vancouver WA 98686 USA
Dr. Slowey is the Founder and Owner of Oasis Diagnostics® Corporation and its subsidiary Company, Bamburgh Marrsh LLC, founded in 2002, each are pioneers in the area of oral fluid diagnostics and testing. Dr Slowey’s background is in Organic Chemistry; after being awarded his Doctorate from the University of Newcastle-upon-Tyne (UK), he spent several years as a Post Doctoral Fellow in Canada then 5 years in the pharmaceutical industry with Sterling Drug [UK]. He has over 32 years of experience in the clinical diagnostic and pharmaceutical industries combined. Over the years he has held positions as Director of International Sales and Chief Operating Officer (COO) and Vice President of Sales and Marketing for companies that were the original pioneers in the development of saliva diagnostic rapid tests for infectious diseases, and oral fluid collection devices. He has extensive experience in structuring strategic alliances and license agreements with both start-up and Fortune 500 companies. Dr Slowey has 30 publications in peer-reviewed journals, fifteen (15) issued patents, twelve (12) filed patent applications and he has made a number of oral presentations at key scientific symposia on a variety of subjects including HIV diagnosis, nucleic acid testing, the status of oral fluid testing, the Japanese Healthcare Business and Thyrotropin Receptor Antibody Assays for the Diagnosis of Graves’ Disease.
Dr Slowey is the Founder and Co-Organizer of the North American Saliva Symposium [NASS, www.salivasymposium.com ] and is a Director of a small teaching college in Kampala, Uganda.
Saliva- the Ideal Specimen for Liquid Biopsy
|Traditionally, tissue biopsy has been the specimen of choice for investigation of potential malignancies, but with the recent findings that tumor DNA can be found and adequately detected in blood samples, there has been a major shift and interest in evaluating blood samples for “liquid biopsy” testing. Significant investments are being made by industry in identifying “liquid biopsy” tests that can be used as either adjuncts or replacements for tissue biopsies and investors are providing funding to back the development of such tests.
This presentation looks at the current market climate and players involved in the “liquid biopsy” testing area and provides an assessment of tools for the collection of cell free DNA, cell free RNA and exosomes using non-invasive [saliva] specimens that may be used in conjunction with downstream assays [e.g. next generation sequencing, quantitative polymerase chain reaction [qRT-PCR] for the potential diagnosis of multiple cancers.